Composite Endpoint
Definition
A composite endpoint is a study or clinical trial outcome that combines two or more individual outcomes into a single endpoint. For example, a trial might count the first occurrence of death, myocardial infarction, stroke, hospitalisation, dementia, disability, or another defined event as part of one combined outcome. [1] [2]
Why It Matters in Ageing Research
Composite endpoints matter because ageing interventions may be intended to delay several age-related diseases or functional declines rather than one isolated condition. By combining multiple clinically meaningful outcomes, researchers can sometimes study broad effects on multimorbidity, disability, and survival more efficiently, but interpretation depends on whether the components are similar in importance and affected in the same direction. [2] [3] [4]
Common Confusion
- A composite endpoint is not automatically stronger than its individual components.
- A positive composite result can be driven mainly by one component, especially if that component is more common or less clinically important.
- Composite endpoints should be interpreted by looking at the full set of component outcomes, not only the combined result.
Related Reading
References
- FDA-NIH Biomarker Working Group. (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource. https://www.ncbi.nlm.nih.gov/books/NBK338448/
- Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003). Composite outcomes in randomized trials: greater precision but with greater uncertainty? https://doi.org/10.1001/jama.289.19.2554
- Ferreira-González, I., Busse, J. W., Heels-Ansdell, D., Montori, V. M., Akl, E. A., Bryant, D. M., Alonso-Coello, P., Alonso, J., Worster, A., Upadhye, S., Jaeschke, R., Schünemann, H. J., Permanyer-Miralda, G., Pacheco-Huergo, V., Domingo-Salvany, A., Wu, P., Mills, E. J., & Guyatt, G. H. (2007). Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. https://doi.org/10.1136/bmj.39136.682083.AE
- Justice, J. N., Ferrucci, L., Newman, A. B., Aroda, V. R., Bahnson, J. L., Divers, J., Espeland, M. A., Marcovina, S., Pollak, M. N., Kritchevsky, S. B., & Barzilai, N. (2018). A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: Report from the TAME Biomarkers Workgroup. https://doi.org/10.1007/s11357-018-0042-y
This glossary entry is provided for educational purposes only and does not constitute medical advice.